Loading quotes...
Forecast
The analysts' average price target is €1.79 (+30.66%). The median is €1.79 (+30.66%).
| Buy |
2 |
| Hold |
1 |
| Sell |
2 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -4.28m | 24.49% |
| Net profit | -63.02m | 5.03% |
| EBITDA | -63.72m | 1.52% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €54.55m |
Number of shares | 41.1m |
52-week high/low | €1.35 - €0.56 |
| Dividends | No |
Beta | 1.25 |
P/E ratio | -0.85 |
PEG ratio | -0.07 |
P/B ratio | 0.42 |
P/S ratio | 0.00 |
Company profile
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
| Name | Achilles Therapeutics PLC ADR |
| CEO | Iraj Ali |
| Headquarters | London,
United Kingdom |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 31/03/2021 |
| Employees | 204 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ACHL |
Frankfurt | 698.F |
Düsseldorf | 698.DU |
München | 698.MU |
